Market Dynamics: Arthritis - The Ongoing Battle for Supremacy

Published by: Datamonitor

Published: Sep. 5, 2002 - 234 Pages

Table of Contents

Scope

Key data and detailed analysis of the 7 leading country markets: the US, Japan, Germany, France, Italy, Spain, and the UK

In-depth analysis and forecasts for the overall arthritis market as well as breakdowns for the DMARD, NSAID, and HA viscosupplement classes

Examination of the factors driving individual country arthritis markets

Detailed company analysis featuring strengths, weaknesses, forecasted sales, and pipelines

Report Highlights

NSAID and DMARD growth rates are being driven by COX-2s and biologics respectively, showing that not all competitors are enjoying overall market growth. With high growth rates, increasing physician acceptance, higher prices that drive additional market value growth, and a number of promising pipeline products, these drug classes have rapidly become the most important in the treatment of arthritis.

A shift in the RA treatment paradigm towards more aggressive, early therapy has contributed heavily to strong sales for DMARDs, particularly biologics. As a result, DMARDs now represent over 12% of the global arthritis market.

The fierce competition between Pfizer and Merck for control of the arthritis leadership continues to grow with the success of COX-2 inhibitors. Reports of adverse events and the launch of 2nd-generation products is not only impacting
the current market, but will shape the future of competition within the arthritis market.

Reasons to Purchase

Understand your competitor’s strengths and weaknesses, while identifying potential licensing, co-promotion, and partnership opportunities.

Assess the potential of key drug classes and the overall arthritis drug market, as well as the factors key to each product’s success.

Attain knowledge beyond current market conditions, with an understanding of the launches and events that will both help and hinder each product.

With detailed Datamonitor forecasts, plan your future strategy with confidence and a higher degree of success.

DRIVERS AND TRENDS

Overview of the factors shaping the global arthritis market, and country markets around the world. Understand the key factors that have determined the relative successes of arthritis drug classes and individual products competing on the arthritis market today.

Which products are benefiting the most from physician perception, patient demand, and strong clinical results?

What companies are suffering as COX-2 inhibitors and biologics continue to play a greater role in the market?

What pipeline products are set to make the biggest splash?

PATIENT POTENTIAL

Understand the demographics that shape the market in this highly-age dependent disease. An examination of the key unmet needs in the treatment of arthritis is also presented.

Evaluating the prevalence of OA and RA

The key treatment patterns for arthritis

Unmet needs in arthritis, by increasing level of importance

GLOBAL MARKET ANALYSIS

The analysis of the global arthritis market is presented in this chapter, segmented by the following drug classes: NSAIDs, DMARDs, Non-opioid analgesics, Opioids, Opioid combinations, Steroids, Viscosupplements
Global growth and sales by drug class

What factors are driving growth, both by class and overall?

Examining the key NSAIDs, DMARDs, and HA Viscosupplements that are not only driving growth, but shaping the market

DMARDS

Examining the impact of biologics

NSAIDs

The battle heats up

HA Viscosupplements

The three products dominating the global market

GLOBAL PLAYERS

An in-depth look at the portfolios and pipelines of eight major players in the arthritis market, and the changing dynamics that have propelled some companies to success.

RA and OA focused companies

A look at who controls the market

Evaluating the pipelines of the market leaders

Pharmacia

Riding the success of COX-2’s until takeover

Merck

A rocky road to catching up

Amgen

Biotech’s role in the arthritis market

Johnson & Johnson

Banking on Remicade success

Novartis

NSAID sales taking a beating

GlaxoSmithKline

Struggling arthritis portfolio

Aventis

Can Arava lead the way?

Wyeth

Wyeth’s key: partner product diversity

2000 COUNTRY ANALYSIS

Examines the overall trends and individual products that have had the greatest impact on the arthritis markets in the US, Japan, France, Germany, Italy, Spain, and the UK.

Identify and understand the large variations between markets

An examination of cost-cutting, fixed prices, and reimbursement

How US and European companies can compete in Japan

MARKET FORECASTS

Based on the degree of satisfaction of unmet need, the order of market entry, and events that impact the potential patient population, competitive scenario, and other factors, Datamonitor has forecasted the sales of the key products and drug classes from 2002-2010

The rise and (eventual) fall of Celebrex and Vioxx

The product that will challenge Remicade and Enbrel

Pfizer/Pharmacia vs. Merck vs…..

ACTION POINTS

Companies without a strong pipeline DMARD or COX-2 must evaluate early pipeline products to make a future market impact.

In order to challenge the Celebrex/Bextra franchise, competitors are going to have to establish a strong safety profile and look for key indications that will guarantee a high level of sales outside the realm of competition with Pfizer.

DATASETS

Table 1: Global sales in the arthritis market by drug class, 2001-10

Table 2: Global sales for leading drugs in the arthritis market, 2001-10

Table 3: Arthritis Prevalence by Country, Population (000’s), 2000-10e

Table 4: Advantages and Disadvantages of NSAIDs , 2002

Table 5: Advantages and Disadvantages of DMARDs, 2002

Table 6: Advantages and Disadvantages of HA viscosupplements, 2002

Table 7: Global sales in the arthritis market by drug class, 1999-2001

Table 8: Sales growth in the global arthritis market by drug class, 1997-2001

Table 9: Factors affecting arthritis drug class growth, 1997-2001

Table 10: DMARDs class profile, 2002

Table 11: Global sales of the leading branded DMARDs, 1999-2001

Table 12: Summary of DMARDs SWOT analyses

Table 13: Sales growth in the DMARDs market, 1997-2001

Table 14: Enbrel: Key Facts, 2002

Table 15: Remicade: Key Facts, 2002

Table 16: Arava: Key Facts, 2002

Table 17: NSAIDs class profile, 2002

Table 18: Global sales of the 10 leading branded NSAIDs, 1999-2001

Table 19: Sales growth in the NSAIDs market, 1997-2001

Table 20: Celebrex: Key Facts, 2002

Table 21: Bextra: Key Facts, 2002

Table 22: ACR20 response rate in RA 3 month trial

Table 23: Vioxx: Key Facts, 2002

Table 24: Arcoxia: Key Facts, 2002

Table 25: Arcoxia mean change from baseline rate after 4 weeks

Table 26: Arcoxia mean change from baseline rate after 12 weeks

Table 27: Voltaren: Key Facts, 2002

Table 28: Hyalgan: Key Facts, 2002

Table 29: Supartz: Key Facts, 2002

Table 30: Synvisc: Key Facts, 2002

Table 31: Pfizer/Pharmacia’s key marketed arthritis products, 2000-01

Table 32: Merck’s key marketed arthritis products, 2000-01

Table 33: Amgen’s key marketed arthritis products, 2000-01

Table 34: Johnson & Johnson’s key marketed arthritis products, 2000-01

Table 35: Breakdown of remicade sales by marketing partner, 1998-2001

Table 36: Novartis’s key marketed arthritis products, 2000-01

Table 37: Aventis’ key marketed arthritis products, 2000-01

Table 38: Global arthritis market sales by country, 1999-2000

Table 39: Sales of arthritis drugs by country and class, 2000

Table 40: Arthritis sales by drug class in the US, 1999-2000

Table 41 shows the leading arthritis products in the US market, 1999-2000.

Table 42: Leading Arthritis Products in the US, 1999-2000

Table 43 shows recent significant drug launches in the US arthritis market in

2000.

Table 44: Promising Recent Arthritis Drug Launches in the US, 2000

Table 45 shows the drugs in decline for the US arthritis market in 2000.

Table 46: Arthritis Drugs in Decline in the US, 2000

Table 47: Leading companies in the US arthritis market, 1999-2000

Table 48: Arthritis Sales by Market Class in Japan, 1999-2000

Table 49: Leading Arthritis Products in Japan, 1999-2000

Table 50: Arthritis Drugs in Decline in Japan, 2000

Table 51: Leading companies in the Japanese arthritis market, 1999-2000

Table 52: Arthritis Sales by Market Class in France, 1999-2000

Table 53: Leading Arthritis Products in France, 1999-2000

Table 54: Promising Recent Launches in France, 2000

Table 55: Arthritis Drugs in Decline in France, 2000

Table 56: Leading companies in the French arthritis market, 1998-1999

Table 57: Arthritis Sales by Market Class in Germany, 1999-2000

Table 58: Leading Arthritis Products in Germany, 1999-2000

Table 59: Promising Recent Arthritis Launches in Germany, 2000

Table 60: Arthritis Drugs in Decline in Germany, 2000

Table 61: Leading companies in the German arthritis market, 1999-2000

Table 62: Arthritis Sales by Market Class in Italy, 1999-2000

Table 63: Leading Arthritis Products in Italy, 1999-2000

Table 64: Promising Recent Arthritis Launches in Italy, 2000

Table 65: Arthritis Drugs in Decline in Italy, 2000

Table 66: Leading companies in the Italian arthritis market, 1999-2000

Table 67: Arthritis Sales by Market Class in Spain, 1999-2000

Table 68: Leading Arthritis Products in Spain, 1999-2000

Table 69: Promising Recent Arthritis Launches in Spain, 2000

Table 70: Arthritis Drugs in Decline in Spain, 2000

Table 71: Leading companies in the Spanish arthritis market, 1999-2000

Table 72: Arthritis Sales by Market Class in UK, 1998-1999

Table 73: Leading Arthritis Products in the UK, 1999-20000

Table 74: Promising Recent Arthritis Launches in the UK, 2000

Table 75: Arthritis drugs in decline in the UK, 2000

Table 76: Leading companies in the UK arthritis market, 1999-2000

Table 77: Arthritis market forecast, 2000-10

Table 78: Factors affecting the arthritis market, 2000-10

Table 79: Key events affecting arthritis market forecasts at the drug class

level

Table 80: Events affecting leading NSAID brand forecasts, 2002-10

Table 81: Marketed and pipeline NSAID forecasts, ($m), 2000-10

Table 82: Events affecting leading DMARD brand forecasts, 2002-10

Table 83: Marketed and pipeline DMARD forecasts, ($m), 2000-10

Table 84: Events affecting leading steroid brand forecasts, 2002-10

Table 85: Marketed steroids forecasts, 2000-2010

Table 86: Factors affecting individual HA viscosupplements, 2002-10

Table 87: Marketed HA viscosupplements forecasts, ($m), 2000-10

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.